Actively Recruiting
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Led by University of Oxford · Updated on 2026-02-19
3800
Participants Needed
7
Research Sites
274 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.
CONDITIONS
Official Title
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient understands study procedures and can give informed consent
- Adults aged 18 to 60 years, male or female, with early symptomatic COVID-19
- Positive SARS-CoV-2 test by lateral flow antigen or PCR within the last 24 hours with Ct value less than 25
- COVID-19 symptoms for less than 4 days (96 hours)
- Oxygen saturation of 96% or higher at screening
- Able to walk unaided and perform activities of daily living
- Willing and able to adhere to all study procedures including follow-up visits and contact availability
You will not qualify if you...
- Taking any other medications or drugs that may interfere with the study
- Having any chronic illness or condition requiring long-term treatment or significant comorbidity such as diabetes or obesity
- Laboratory abnormalities found at screening
- For females: pregnant, actively trying to become pregnant, or breastfeeding
- Known allergy or intolerance to any of the study treatments
- Currently participating in another COVID-19 treatment or vaccine trial
- Evidence of pneumonia (imaging not required for diagnosis)
- Healthy women using oral contraceptive pills are eligible
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Universidade Federal de Minas Gerais
Minas Gerais, Brazil
Actively Recruiting
2
Laos-Oxford-Mahosot Wellcome Trust Research Unit
Vientiane, Laos, 01000
Actively Recruiting
3
Sukraraj Tropical & Infectious Disease Hospital
Kathmandu, Nepal
Actively Recruiting
4
The Aga Khan University Hospital
Karachi, Pakistan
Terminated
5
Vajira hospital
Bangkok, Thailand, 10300
Terminated
6
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand, 10400
Actively Recruiting
7
Bangplee Hospital
Mueang Samut Prakan, Thailand, 10540
Terminated
Research Team
W
William Schilling, MD
CONTACT
N
Nicholas J White, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
19
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here